Selskabsmeddelelse

Active Biotech Interim Report Q3 2022

THIRD QUARTER IN BRIEF

Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4)
The first part of the multiple dose of laquinimod eye drops in the phase I study has been completed without any serious side effects that can be linked to laquinimod and the study has been expanded with another dose group
Active Biotech announces final outcome of the company’s rights issue (Sep 7)

EVENTS AFTER THE END OF THE PERIOD

Active Biotech further strengthens the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24)

Financial summary

SEK M	Jul-Sep		Jan-Sep		Full year
	2022 2021		2022 2021		2021
Net sales	-	-	-	-	-
Operating profit/loss	-13,4	-11,3	-42,6	-33,6	-49,8
Profit/loss after tax	-13,4	-11,2	-43,4	-33,7	-49,8
Earnings per share (SEK)	-0,06	-0,05	-0,19	-0,16	-0,24
Cash and cash equivalents (at close of period)			55,0	68,4	53,1

The report is also available at www.activebiotech.com.

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.